|
1
|
Pignata S and Vermorken JB: Ovarian cancer
in the elderly. Crit Rev Oncol Hematol. 49:77–86. 2004. View Article : Google Scholar
|
|
2
|
Boren T, Xiong Y, Hakam A, et al:
MicroRNAs and their target messenger RNAs associated with ovarian
cancer response to chemotherapy. Gynecol Oncol. 113:249–255. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Liu JF, Hirsch MS, Lee H and Matulonis UA:
Prognosis and hormone receptor status in older and younger patients
with advanced-stage papillary serous ovarian carcinoma. Gynecol
Oncol. 115:401–406. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Moore DH, Kauderer JT, Bell J, Curtin JP
and Van Le L: An assessment of age and other factors influencing
protocol versus alternative treatments for patients with epithelial
ovarian cancer referred to member institutions: a Gynecologic
Oncology Group study. Gynecol Oncol. 94:368–374. 2004. View Article : Google Scholar
|
|
5
|
Shih KK, Qin LX, Tanner EJ, et al: A
microRNA survival signature (MiSS) for advanced ovarian cancer.
Gynecol Oncol. 121:444–450. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yancik R, Ries LG and Yates JW: Ovarian
cancer in the elderly: an analysis of Surveillance, Epidemiology,
and End Results Program data. Am J Obstet Gynecol. 154:639–647.
1986. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chan JK, Teoh D, Hu JM, Shin JY, Osann K
and Kapp DS: Do clear cell ovarian carcinomas have poorer prognosis
compared to other epithelial cell types? A study of 1411 clear cell
ovarian cancers. Gynecol Oncol. 109:370–376. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wyman SK, Parkin RK, Mitchell PS, et al:
Repertoire of microRNAs in epithelial ovarian cancer as determined
by next generation sequencing of small RNA cDNA libraries. PLoS
One. 4:e53112009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Van Jaarsveld MT, Helleman J, Berns EM and
Wiemer EA: MicroRNAs in ovarian cancer biology and therapy
resistance. Int J Biochem Cell Biol. 42:1282–1290. 2010.PubMed/NCBI
|
|
10
|
Sugiyama T, Kamura T, Kigawa J, et al:
Clinical characteristics of clear cell carcinoma of the ovary: a
distinct histologic type with poor prognosis and resistance to
platinum-based chemotherapy. Cancer. 88:2584–2589. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yoshida S, Furukawa N, Haruta S, et al:
Theoretical model of treatment strategies for clear cell carcinoma
of the ovary: focus on perspectives. Cancer Treat Rev. 35:608–615.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pectasides D, Pectasides E, Psyrri A and
Economopoulos T: Treatment issues in clear cell carcinoma of the
ovary: a different entity? Oncologist. 11:1089–1094. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Snowdon J, Zhang X, Childs T, Tron VA and
Feilotter H: The microRNA-200 family is upregulated in endometrial
carcinoma. PLoS One. 6:e228282011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cui S, Li C, Ema M, Weinstein J and
Quaggin SE: Rapid isolation of glomeruli coupled with gene
expression profiling identifies downstream targets in Pod1 knockout
mice. J Am Soc Nephrol. 16:3247–3255. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
American Cancer Society. Global Cancer
Facts and Figures 2007. American Cancer Society Inc; Atlanta, GA:
2007
|
|
16
|
Howlader N, Noone AM, Krapcho M, Neyman N,
Aminou R, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H,
Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ and Cronin KA:
SEER Cancer Statistics Review: 1975–2008. National Institutes of
Health; Bethesda, MD: 2011
|
|
17
|
Kim MS, In SG, Park OJ, et al: Increased
expression of activating transcription factor 3 is related to the
biologic behavior of cutaneous squamous cell carcinomas. Hum
Pathol. 42:954–959. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li ZD, Hu XW, Wang YT and Fang J: Apigenin
inhibits proliferation of ovarian cancer A2780 cells through Id1.
FEBS Lett. 583:1999–2003. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hai T and Hartman MG: The molecular
biology and nomenclature of the activating transcription
factor/cAMP responsive element binding family of transcription
factors: activating transcription factor proteins and homeostasis.
Gene. 273:1–11. 2001. View Article : Google Scholar
|
|
20
|
Thompson MR, Xu D and Williams BR: ATF3
transcription factor and its emerging roles in immunity and cancer.
J Mol Med (Berl). 87:1053–1060. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Pelzer AE, Bektic J, Haag P, et al: The
expression of transcription factor activating transcription factor
3 in the human prostate and its regulation by androgen in prostate
cancer. J Urol. 175:1517–1522. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Janz M, Hummel M, Truss M, et al:
Classical Hodgkin lymphoma is characterized by high constitutive
expression of activating transcription factor 3 (ATF3), which
promotes viability of Hodgkin/Reed-Sternberg cells. Blood.
107:2536–2539. 2006. View Article : Google Scholar
|
|
23
|
Bandyopadhyay S, Wang Y, Zhan R, et al:
The tumor metastasis suppressor gene Drg-1 down-regulates the
expression of activating transcription factor 3 in prostate cancer.
Cancer Res. 66:11983–11990. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ishiguro T, Nagawa H, Naito M and Tsuruo
T: Inhibitory effect of ATF3 antisense oligonucleotide on ectopic
growth of HT29 human colon cancer cells. Jpn J Cancer Res.
91:833–836. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hsieh SY, Huang SF, Yu MC, et al:
Stathmin1 overexpression associated with polyploidy, tumor-cell
invasion, early recurrence, and poor prognosis in human hepatoma.
Mol Carcinog. 49:476–487. 2010.PubMed/NCBI
|
|
26
|
Lee HS, Lee DC, Park MH, et al: STMN2 is a
novel target of beta-catenin/TCF-mediated transcription in human
hepatoma cells. Biochem Biophys Res Commun. 345:1059–1067. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Su D, Smith SM, Preti M, et al: Stathmin
and tubulin expression and survival of ovarian cancer patients
receiving platinum treatment with and without paclitaxel. Cancer.
115:2453–2463. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ponzielli R, Katz S, Barsyte-Lovejoy D and
Penn LZ: Cancer therapeutics: targeting the dark side of Myc. Eur J
Cancer. 41:2485–2501. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lee YY, Kim TJ, Kim MJ, et al: Prognosis
of ovarian clear cell carcinoma compared to other histological
subtypes: a meta-analysis. Gynecol Oncol. 122:541–547. 2011.
View Article : Google Scholar : PubMed/NCBI
|
